{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:25:56Z","timestamp":1792553156169,"version":"4.5.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-023-02184-6","type":"journal-article","created":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T17:01:36Z","timestamp":1696698096000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Recent advancement in targeted therapy and role of emerging technologies to treat cancer"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0924-5701","authenticated-orcid":false,"given":"Shrikant","family":"Barot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henis","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Ban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,7]]},"reference":[{"key":"2184_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"key":"2184_CR2","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339:1546\u201358. https:\/\/doi.org\/10.1126\/science.1235122.","journal-title":"Science"},{"key":"2184_CR3","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nature07943","volume":"458","author":"MR Stratton","year":"2009","unstructured":"Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458:719\u201324. https:\/\/doi.org\/10.1038\/nature07943.","journal-title":"Nature"},{"key":"2184_CR4","doi-asserted-by":"publisher","first-page":"13306","DOI":"10.1073\/pnas.0405220101","volume":"101","author":"W Pao","year":"2004","unstructured":"Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306\u201311. https:\/\/doi.org\/10.1073\/pnas.0405220101.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2184_CR5","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1126\/science.1096502","volume":"304","author":"Y Samuels","year":"2004","unstructured":"Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554\u2013554. https:\/\/doi.org\/10.1126\/science.1096502.","journal-title":"Science"},{"key":"2184_CR6","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior IA, Hood FE, Hartley JL. The frequency of Ras mutations in cancer. Can Res. 2020;80:2969\u201374. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-3682.","journal-title":"Can Res"},{"key":"2184_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/358015a0","volume":"358","author":"DP Lane","year":"1992","unstructured":"Lane DP. p53, guardian of the genome. Nature. 1992;358:15\u20136. https:\/\/doi.org\/10.1038\/358015a0.","journal-title":"Nature"},{"key":"2184_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/cdd.2017.174","volume":"25","author":"KD Sullivan","year":"2018","unstructured":"Sullivan KD, Galbraith MD, Andrysik Z, Espinosa JM. Mechanisms of transcriptional regulation by p53. Cell Death Differ. 2018;25:133\u201343. https:\/\/doi.org\/10.1038\/cdd.2017.174.","journal-title":"Cell Death Differ"},{"key":"2184_CR9","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860\u20137. https:\/\/doi.org\/10.1038\/nature01322.","journal-title":"Nature"},{"key":"2184_CR10","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436\u201344. https:\/\/doi.org\/10.1038\/nature07205.","journal-title":"Nature"},{"key":"2184_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/cncr.20365","volume":"101","author":"JR Daling","year":"2004","unstructured":"Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101:270\u201380. https:\/\/doi.org\/10.1002\/cncr.20365.","journal-title":"Cancer"},{"key":"2184_CR12","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","volume":"11","author":"S de Sanjose","year":"2010","unstructured":"de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048\u201356. https:\/\/doi.org\/10.1016\/S1470-2045(10)70230-8.","journal-title":"Lancet Oncol"},{"key":"2184_CR13","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1001\/jama.289.24.3243","volume":"289","author":"RT Chlebowski","year":"2003","unstructured":"Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women\u2019s Health Initiative Randomized Trial. JAMA. 2003;289:3243. https:\/\/doi.org\/10.1001\/jama.289.24.3243.","journal-title":"JAMA"},{"key":"2184_CR14","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2011","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(11)60993-8.","journal-title":"Lancet"},{"key":"2184_CR15","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1158\/1055-9965.EPI-04-0715","volume":"14","author":"JK Parsons","year":"2005","unstructured":"Parsons JK, Carter HB, Platz EA, et al. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomark Prev. 2005;14:2257\u201360. https:\/\/doi.org\/10.1158\/1055-9965.EPI-04-0715.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2184_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/5416923","volume":"2018","author":"LTH Phi","year":"2018","unstructured":"Phi LTH, Sari IN, Yang Y-G, et al. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int. 2018;2018:1\u201316. https:\/\/doi.org\/10.1155\/2018\/5416923.","journal-title":"Stem Cells Int"},{"key":"2184_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1582-4934.2005.tb00337.x","volume":"9","author":"G Song","year":"2005","unstructured":"Song G, Ouyang G, Bao S. The activation of Akt\/PKB signaling pathway and cell survival. J Cell Mol Med. 2005;9:59\u201371. https:\/\/doi.org\/10.1111\/j.1582-4934.2005.tb00337.x.","journal-title":"J Cell Mol Med"},{"key":"2184_CR18","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1016\/S1470-2045(21)00639-2","volume":"23","author":"MI Printezi","year":"2022","unstructured":"Printezi MI, Kilgallen AB, Bond MJG, et al. Toxicity and efficacy of chronomodulated chemotherapy: a systematic review. Lancet Oncol. 2022;23:e129\u201343. https:\/\/doi.org\/10.1016\/S1470-2045(21)00639-2.","journal-title":"Lancet Oncol"},{"key":"2184_CR19","doi-asserted-by":"publisher","first-page":"123056","DOI":"10.1016\/j.ijpharm.2023.123056","volume":"641","author":"H Patel","year":"2023","unstructured":"Patel H, Palekar S, Patel A, Patel K. Ibrutinib amorphous solid dispersions with enhanced dissolution at colonic pH for the localized treatment of colorectal cancer. Int J Pharm. 2023;641:123056. https:\/\/doi.org\/10.1016\/j.ijpharm.2023.123056.","journal-title":"Int J Pharm"},{"key":"2184_CR20","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41576-019-0114-6","volume":"20","author":"S Turajlic","year":"2019","unstructured":"Turajlic S, Sottoriva A, Graham T, Swanton C. Resolving genetic heterogeneity in cancer. Nat Rev Genet. 2019;20:404\u201316. https:\/\/doi.org\/10.1038\/s41576-019-0114-6.","journal-title":"Nat Rev Genet"},{"key":"2184_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10549-016-3718-y","volume":"156","author":"MV Dieci","year":"2016","unstructured":"Dieci MV, Smutn\u00e1 V, Scott V, et al. Whole exome sequencing of rare aggressive breast cancer histologies. Breast Cancer Res Treat. 2016;156:21\u201332. https:\/\/doi.org\/10.1007\/s10549-016-3718-y.","journal-title":"Breast Cancer Res Treat"},{"key":"2184_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong L, Li Y, Xiong L, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Sig Transduct Target Ther. 2021;6:1\u201348. https:\/\/doi.org\/10.1038\/s41392-021-00572-w.","journal-title":"Sig Transduct Target Ther"},{"key":"2184_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.7603\/s40681-015-0019-4","volume":"5","author":"VV Padma","year":"2015","unstructured":"Padma VV. An overview of targeted cancer therapy. Biomedicine (Taipei). 2015;5:19. https:\/\/doi.org\/10.7603\/s40681-015-0019-4.","journal-title":"Biomedicine (Taipei)"},{"key":"2184_CR24","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1101\/gad.314617.118","volume":"32","author":"H Gonzalez","year":"2018","unstructured":"Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32:1267\u201384. https:\/\/doi.org\/10.1101\/gad.314617.118.","journal-title":"Genes Dev"},{"key":"2184_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13053-020-00141-2","volume":"18","author":"W Chan","year":"2020","unstructured":"Chan W, Lee M, Yeo ZX, et al. Development and validation of next generation sequencing based 35-gene hereditary cancer panel. Hereditary Cancer Clin Pract. 2020;18:9. https:\/\/doi.org\/10.1186\/s13053-020-00141-2.","journal-title":"Hereditary Cancer Clin Pract"},{"key":"2184_CR26","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1016\/j.csbj.2020.08.019","volume":"18","author":"Z Dlamini","year":"2020","unstructured":"Dlamini Z, Francies FZ, Hull R, Marima R. Artificial intelligence (AI) and big data in cancer and precision oncology. Comput Struct Biotechnol J. 2020;18:2300\u201311. https:\/\/doi.org\/10.1016\/j.csbj.2020.08.019.","journal-title":"Comput Struct Biotechnol J"},{"key":"2184_CR27","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","volume":"31","author":"F Mosele","year":"2020","unstructured":"Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31:1491\u2013505. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.014.","journal-title":"Ann Oncol"},{"key":"2184_CR28","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.3390\/cancers13184564","volume":"13","author":"S Bruzas","year":"2021","unstructured":"Bruzas S, Kuemmel S, Harrach H, et al. Next-generation sequencing-directed therapy in patients with metastatic breast cancer in routine clinical practice. Cancers (Basel). 2021;13:4564. https:\/\/doi.org\/10.3390\/cancers13184564.","journal-title":"Cancers (Basel)"},{"key":"2184_CR29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/antib9030034","volume":"9","author":"D Zahavi","year":"2020","unstructured":"Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies. 2020;9:34. https:\/\/doi.org\/10.3390\/antib9030034.","journal-title":"Antibodies"},{"key":"2184_CR30","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.3390\/molecules25204764","volume":"25","author":"U Hafeez","year":"2020","unstructured":"Hafeez U, Parakh S, Gan HK, Scott AM. Antibody-drug conjugates for cancer therapy. Molecules. 2020;25:4764. https:\/\/doi.org\/10.3390\/molecules25204764.","journal-title":"Molecules"},{"key":"2184_CR31","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ccr.2014.02.025","volume":"25","author":"CL Arteaga","year":"2014","unstructured":"Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25:282\u2013303. https:\/\/doi.org\/10.1016\/j.ccr.2014.02.025.","journal-title":"Cancer Cell"},{"key":"2184_CR32","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/nrc3559","volume":"13","author":"N Tebbutt","year":"2013","unstructured":"Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer. 2013;13:663\u201373. https:\/\/doi.org\/10.1038\/nrc3559.","journal-title":"Nat Rev Cancer"},{"key":"2184_CR33","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10555-016-9649-6","volume":"35","author":"JL Hsu","year":"2016","unstructured":"Hsu JL, Hung M-C. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev. 2016;35:575\u201388. https:\/\/doi.org\/10.1007\/s10555-016-9649-6.","journal-title":"Cancer Metastasis Rev"},{"key":"2184_CR34","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrc.2017.84","volume":"17","author":"J Rotow","year":"2017","unstructured":"Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017;17:637\u201358. https:\/\/doi.org\/10.1038\/nrc.2017.84.","journal-title":"Nat Rev Cancer"},{"key":"2184_CR35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","volume":"79","author":"R Roskoski","year":"2014","unstructured":"Roskoski R. The ErbB\/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34\u201374. https:\/\/doi.org\/10.1016\/j.phrs.2013.11.002.","journal-title":"Pharmacol Res"},{"key":"2184_CR36","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.clcc.2017.03.001","volume":"16","author":"N Takegawa","year":"2017","unstructured":"Takegawa N, Yonesaka K. HER2 as an emerging oncotarget for colorectal cancer treatment after failure of anti-epidermal growth factor receptor therapy. Clin Colorectal Cancer. 2017;16:247\u201351. https:\/\/doi.org\/10.1016\/j.clcc.2017.03.001.","journal-title":"Clin Colorectal Cancer"},{"key":"2184_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-013-0252-z","volume":"17","author":"N Boku","year":"2014","unstructured":"Boku N. HER2-positive gastric cancer. Gastric Cancer. 2014;17:1\u201312. https:\/\/doi.org\/10.1007\/s10120-013-0252-z.","journal-title":"Gastric Cancer"},{"key":"2184_CR38","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMcibr1909386","volume":"381","author":"DF Hayes","year":"2019","unstructured":"Hayes DF. HER2 and breast cancer\u2014a phenomenal success story. N Engl J Med. 2019;381:1284\u20136. https:\/\/doi.org\/10.1056\/NEJMcibr1909386.","journal-title":"N Engl J Med"},{"key":"2184_CR39","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/jamaoncol.2019.1467","volume":"5","author":"F Pietrantonio","year":"2019","unstructured":"Pietrantonio F, Morano F, Corallo S, et al. Maintenance therapy with Panitumumab alone vs Panitumumab plus fluorouracil-Leucovorin in patients with RAS wild-type metastatic colorectal cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5:1268\u201375. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1467.","journal-title":"JAMA Oncol"},{"key":"2184_CR40","volume-title":"Medical genetics summaries","author":"L Dean","year":"2012","unstructured":"Dean L, Kane M, et al. Cetuximab therapy and RAS and BRAF genotype. In: Pratt VM, Scott SA, Pirmohamed M, et al., editors. Medical genetics summaries. Bethesda: National Center for Biotechnology Information; 2012."},{"key":"2184_CR41","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, K\u00f6hne C-H, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408\u201317. https:\/\/doi.org\/10.1056\/NEJMoa0805019.","journal-title":"N Engl J Med"},{"key":"2184_CR42","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for First-Line Treatment of PD-L1\u2013Selected Patients with NSCLC. N Engl J Med. 2020;383:1328\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1917346.","journal-title":"N Engl J Med"},{"key":"2184_CR43","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1093\/annonc\/mdy411","volume":"29","author":"AD Colevas","year":"2018","unstructured":"Colevas AD, Bahleda R, Braiteh F, et al. Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. Ann Oncol. 2018;29:2247\u201353. https:\/\/doi.org\/10.1093\/annonc\/mdy411.","journal-title":"Ann Oncol"},{"key":"2184_CR44","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","volume":"80","author":"YY Syed","year":"2020","unstructured":"Syed YY. Sacituzumab Govitecan: first approval. Drugs. 2020;80:1019\u201325. https:\/\/doi.org\/10.1007\/s40265-020-01337-5.","journal-title":"Drugs"},{"key":"2184_CR45","doi-asserted-by":"publisher","first-page":"22496","DOI":"10.18632\/oncotarget.4318","volume":"6","author":"DM Goldenberg","year":"2015","unstructured":"Goldenberg DM, Cardillo TM, Govindan SV, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015;6:22496\u2013512. https:\/\/doi.org\/10.18632\/oncotarget.4318.","journal-title":"Oncotarget"},{"key":"2184_CR46","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2028485.","journal-title":"N Engl J Med"},{"key":"2184_CR47","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.3390\/jcm10122544","volume":"10","author":"M Queudeville","year":"2021","unstructured":"Queudeville M, Ebinger M. Blinatumomab in pediatric acute lymphoblastic leukemia\u2014from salvage to first line therapy (a systematic review). JCM. 2021;10:2544. https:\/\/doi.org\/10.3390\/jcm10122544.","journal-title":"JCM"},{"key":"2184_CR48","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18:585\u2013608. https:\/\/doi.org\/10.1038\/s41573-019-0028-1.","journal-title":"Nat Rev Drug Discov"},{"key":"2184_CR49","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40259-019-00400-2","volume":"34","author":"Q Zhao","year":"2020","unstructured":"Zhao Q. Bispecific antibodies for autoimmune and inflammatory diseases: clinical progress to date. BioDrugs. 2020;34:111\u20139. https:\/\/doi.org\/10.1007\/s40259-019-00400-2.","journal-title":"BioDrugs"},{"key":"2184_CR50","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/icb.2014.93","volume":"93","author":"AM Huehls","year":"2015","unstructured":"Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol. 2015;93:290\u20136. https:\/\/doi.org\/10.1038\/icb.2014.93.","journal-title":"Immunol Cell Biol"},{"key":"2184_CR51","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","volume":"388","author":"IM Van Der Sluis","year":"2023","unstructured":"Van Der Sluis IM, De Lorenzo P, Kotecha RS, et al. Blinatumomab added to chemotherapy in infant lymphoblastic leukemia. N Engl J Med. 2023;388:1572\u201381. https:\/\/doi.org\/10.1056\/NEJMoa2214171.","journal-title":"N Engl J Med"},{"key":"2184_CR52","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s40265-021-01561-7","volume":"81","author":"YY Syed","year":"2021","unstructured":"Syed YY. Amivantamab: first approval. Drugs. 2021;81:1349\u201353. https:\/\/doi.org\/10.1007\/s40265-021-01561-7.","journal-title":"Drugs"},{"key":"2184_CR53","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/JCO.21.00662","volume":"39","author":"K Park","year":"2021","unstructured":"Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR Exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS Phase I Study. J Clin Oncol. 2021;39:3391\u2013402. https:\/\/doi.org\/10.1200\/JCO.21.00662.","journal-title":"J Clin Oncol"},{"key":"2184_CR54","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","volume":"53","author":"P Vormittag","year":"2018","unstructured":"Vormittag P, Gunn R, Ghorashian S, Veraitch FS. A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol. 2018;53:164\u201381. https:\/\/doi.org\/10.1016\/j.copbio.2018.01.025.","journal-title":"Curr Opin Biotechnol"},{"key":"2184_CR55","doi-asserted-by":"publisher","first-page":"6223","DOI":"10.3390\/ijms20246223","volume":"20","author":"S Stock","year":"2019","unstructured":"Stock S, Schmitt M, Sellner L. Optimizing manufacturing protocols of chimeric antigen receptor T cells for improved anticancer immunotherapy. Int J Mol Sci. 2019;20:6223. https:\/\/doi.org\/10.3390\/ijms20246223.","journal-title":"Int J Mol Sci"},{"key":"2184_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtm.2019.09.007","volume":"16","author":"MS Pampusch","year":"2020","unstructured":"Pampusch MS, Haran KP, Hart GT, et al. Rapid transduction and expansion of transduced T cells with maintenance of central memory populations. Mol Ther. 2020;16:1\u201310. https:\/\/doi.org\/10.1016\/j.omtm.2019.09.007.","journal-title":"Mol Ther"},{"key":"2184_CR57","first-page":"1","volume":"36","author":"L Vannucci","year":"2013","unstructured":"Vannucci L, Lai M, Chiuppesi F, et al. Viral vectors: a look back and ahead on gene transfer technology. New Microbiol. 2013;36:1\u201322.","journal-title":"New Microbiol"},{"key":"2184_CR58","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","volume":"7","author":"LJ Rupp","year":"2017","unstructured":"Rupp LJ, Schumann K, Roybal KT, et al. CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017;7:737. https:\/\/doi.org\/10.1038\/s41598-017-00462-8.","journal-title":"Sci Rep"},{"key":"2184_CR59","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","volume":"12","author":"S Guedan","year":"2019","unstructured":"Guedan S, Calderon H, Posey AD, Maus MV. Engineering and design of chimeric antigen receptors. Mol Ther. 2019;12:145\u201356. https:\/\/doi.org\/10.1016\/j.omtm.2018.12.009.","journal-title":"Mol Ther"},{"key":"2184_CR60","unstructured":"CAR-T design: Elements and their synergistic function\u2014ScienceDirect. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352396420303078. Accessed 15 May 2023"},{"key":"2184_CR61","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","volume":"66","author":"FC Thistlethwaite","year":"2017","unstructured":"Thistlethwaite FC, Gilham DE, Guest RD, et al. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunol Immunother. 2017;66:1425\u201336. https:\/\/doi.org\/10.1007\/s00262-017-2034-7.","journal-title":"Cancer Immunol Immunother"},{"key":"2184_CR62","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrd4597","volume":"14","author":"SJC van der Stegen","year":"2015","unstructured":"van der Stegen SJC, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov. 2015;14:499\u2013509. https:\/\/doi.org\/10.1038\/nrd4597.","journal-title":"Nat Rev Drug Discov"},{"key":"2184_CR63","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","volume":"15","author":"M Chmielewski","year":"2015","unstructured":"Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15:1145\u201354. https:\/\/doi.org\/10.1517\/14712598.2015.1046430.","journal-title":"Expert Opin Biol Ther"},{"key":"2184_CR64","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","volume":"120","author":"N Tokarew","year":"2019","unstructured":"Tokarew N, Ogonek J, Endres S, et al. Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer. 2019;120:26\u201337. https:\/\/doi.org\/10.1038\/s41416-018-0325-1.","journal-title":"Br J Cancer"},{"key":"2184_CR65","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/jha2.338","volume":"3","author":"S Sengsayadeth","year":"2022","unstructured":"Sengsayadeth S, Savani BN, Oluwole O, Dholaria B. Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice. JHaem. 2022;3:6\u201310. https:\/\/doi.org\/10.1002\/jha2.338.","journal-title":"JHaem"},{"key":"2184_CR66","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386:640\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2116133.","journal-title":"N Engl J Med"},{"key":"2184_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:1\u201311. https:\/\/doi.org\/10.1038\/s41408-021-00459-7.","journal-title":"Blood Cancer J"},{"key":"2184_CR68","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625\u201338. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2184_CR69","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8:958\u201371. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1319.","journal-title":"Cancer Discov"},{"key":"2184_CR70","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella M, Xu J, Barrett DM, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018;24:1499\u2013503. https:\/\/doi.org\/10.1038\/s41591-018-0201-9.","journal-title":"Nat Med"},{"key":"2184_CR71","doi-asserted-by":"publisher","first-page":"eaav3888","DOI":"10.1126\/scitranslmed.aav3888","volume":"10","author":"CS Hinrichs","year":"2018","unstructured":"Hinrichs CS. Self-defeating CAR-Ts protect leukemic cells. Sci Transl Med. 2018;10:eaav3888. https:\/\/doi.org\/10.1126\/scitranslmed.aav3888.","journal-title":"Sci Transl Med"},{"key":"2184_CR72","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","volume":"3","author":"MJ Lin","year":"2022","unstructured":"Lin MJ, Svensson-Arvelund J, Lubitz GS, et al. Cancer vaccines: the next immunotherapy frontier. Nat Cancer. 2022;3:911\u201326. https:\/\/doi.org\/10.1038\/s43018-022-00418-6.","journal-title":"Nat Cancer"},{"key":"2184_CR73","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","volume":"17","author":"MA Cheever","year":"2011","unstructured":"Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011;17:3520\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-3126.","journal-title":"Clin Cancer Res"},{"key":"2184_CR74","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1093\/jnci\/djaa021","volume":"112","author":"RA Madan","year":"2020","unstructured":"Madan RA, Antonarakis ES, Drake CG, et al. Putting the pieces together: completing the mechanism of action jigsaw for Sipuleucel-T. JNCI. 2020;112:562\u201373. https:\/\/doi.org\/10.1093\/jnci\/djaa021.","journal-title":"JNCI"},{"key":"2184_CR75","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/Nejmoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411\u201322. https:\/\/doi.org\/10.1056\/Nejmoa1001294.","journal-title":"N Engl J Med"},{"key":"2184_CR76","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jaad.2020.01.039","volume":"83","author":"K Haitz","year":"2020","unstructured":"Haitz K, Khosravi H, Lin JY, et al. Review of talimogene laherparepvec: a first-in-class oncolytic viral treatment of advanced melanoma. J Am Acad Dermatol. 2020;83:189\u201396. https:\/\/doi.org\/10.1016\/j.jaad.2020.01.039.","journal-title":"J Am Acad Dermatol"},{"key":"2184_CR77","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/sj.gt.3301885","volume":"10","author":"BL Liu","year":"2003","unstructured":"Liu BL, Robinson M, Han Z-Q, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10:292\u2013303. https:\/\/doi.org\/10.1038\/sj.gt.3301885.","journal-title":"Gene Ther"},{"key":"2184_CR78","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S1470-2045(01)00618-0","volume":"3","author":"LK Hawkins","year":"2002","unstructured":"Hawkins LK, Lemoine NR, Kirn D. Oncolytic biotherapy: a novel therapeutic platform. Lancet Oncol. 2002;3:17\u201326. https:\/\/doi.org\/10.1016\/S1470-2045(01)00618-0.","journal-title":"Lancet Oncol"},{"key":"2184_CR79","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-016-0158-5","volume":"4","author":"H Rehman","year":"2016","unstructured":"Rehman H, Silk AW, Kane MP, Kaufman HL. Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother Cancer. 2016;4:53. https:\/\/doi.org\/10.1186\/s40425-016-0158-5.","journal-title":"J Immunother Cancer"},{"key":"2184_CR80","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3390\/cancers13061383","volume":"13","author":"PF Ferrucci","year":"2021","unstructured":"Ferrucci PF, Pala L, Conforti F, Cocorocchio E. Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma. Cancers (Basel). 2021;13:1383. https:\/\/doi.org\/10.3390\/cancers13061383.","journal-title":"Cancers (Basel)"},{"key":"2184_CR81","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RHI Andtbacka","year":"2015","unstructured":"Andtbacka RHI, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780\u20138. https:\/\/doi.org\/10.1200\/JCO.2014.58.3377.","journal-title":"J Clin Oncol"},{"key":"2184_CR82","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6:1078\u201394. https:\/\/doi.org\/10.1038\/s41578-021-00358-0.","journal-title":"Nat Rev Mater"},{"key":"2184_CR83","doi-asserted-by":"publisher","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","volume":"15","author":"R Tenchov","year":"2021","unstructured":"Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid nanoparticles\u2500from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano. 2021;15:16982\u20137015. https:\/\/doi.org\/10.1021\/acsnano.1c04996.","journal-title":"ACS Nano"},{"key":"2184_CR84","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1089\/nat.2018.0721","volume":"28","author":"JA Kulkarni","year":"2018","unstructured":"Kulkarni JA, Cullis PR, van der Meel R. Lipid nanoparticles enabling gene therapies: from concepts to clinical utility. Nucleic Acid Ther. 2018;28:146\u201357. https:\/\/doi.org\/10.1089\/nat.2018.0721.","journal-title":"Nucleic Acid Ther"},{"key":"2184_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06063-y","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023. https:\/\/doi.org\/10.1038\/s41586-023-06063-y.","journal-title":"Nature"},{"key":"2184_CR86","doi-asserted-by":"publisher","first-page":"592","DOI":"10.18632\/aging.101415","volume":"10","author":"D Jia","year":"2018","unstructured":"Jia D, Li S, Li D, et al. Mining TCGA database for genes of prognostic value in glioblastoma microenvironment. Aging. 2018;10:592\u2013605. https:\/\/doi.org\/10.18632\/aging.101415.","journal-title":"Aging"},{"key":"2184_CR87","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5114\/wo.2014.47136","volume":"1A","author":"K Tomczak","year":"2015","unstructured":"Tomczak K, Czerwi\u0144ska P, Wiznerowicz M. Review the cancer genome atlas (TCGA): an immeasurable source of knowledge. WO. 2015;1A:68\u201377. https:\/\/doi.org\/10.5114\/wo.2014.47136.","journal-title":"WO"},{"key":"2184_CR88","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/nature08987","volume":"464","author":"The International Cancer Genome Consortium","year":"2010","unstructured":"The International Cancer Genome Consortium. International network of cancer genome projects. Nature. 2010;464:993\u20138. https:\/\/doi.org\/10.1038\/nature08987.","journal-title":"Nature"},{"key":"2184_CR89","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41587-019-0055-9","volume":"37","author":"J Zhang","year":"2019","unstructured":"Zhang J, Bajari R, Andric D, et al. The International Cancer Genome Consortium Data Portal. Nat Biotechnol. 2019;37:367\u20139. https:\/\/doi.org\/10.1038\/s41587-019-0055-9.","journal-title":"Nat Biotechnol"},{"key":"2184_CR90","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/nbt1210-1248","volume":"28","author":"M Uhlen","year":"2010","unstructured":"Uhlen M, Oksvold P, Fagerberg L, et al. Towards a knowledge-based human protein atlas. Nat Biotechnol. 2010;28:1248\u201350. https:\/\/doi.org\/10.1038\/nbt1210-1248.","journal-title":"Nat Biotechnol"},{"key":"2184_CR91","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/pro.3307","volume":"27","author":"PJ Thul","year":"2018","unstructured":"Thul PJ, Lindskog C. The human protein atlas: a spatial map of the human proteome: the human protein atlas. Protein Sci. 2018;27:233\u201344. https:\/\/doi.org\/10.1002\/pro.3307.","journal-title":"Protein Sci"},{"key":"2184_CR92","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nbt.2839","volume":"32","author":"JA Vizca\u00edno","year":"2014","unstructured":"Vizca\u00edno JA, Deutsch EW, Wang R, et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat Biotechnol. 2014;32:223\u20136. https:\/\/doi.org\/10.1038\/nbt.2839.","journal-title":"Nat Biotechnol"},{"key":"2184_CR93","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/nar\/30.1.207","volume":"30","author":"R Edgar","year":"2002","unstructured":"Edgar R. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30:207\u201310. https:\/\/doi.org\/10.1093\/nar\/30.1.207.","journal-title":"Nucleic Acids Res"},{"key":"2184_CR94","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41597-019-0043-4","volume":"6","author":"M Suntsova","year":"2019","unstructured":"Suntsova M, Gaifullin N, Allina D, et al. Atlas of RNA sequencing profiles for normal human tissues. Sci Data. 2019;6:36. https:\/\/doi.org\/10.1038\/s41597-019-0043-4.","journal-title":"Sci Data"},{"key":"2184_CR95","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1093\/bib\/bbz144","volume":"21","author":"Y-C Chiu","year":"2020","unstructured":"Chiu Y-C, Chen H-IH, Gorthi A, et al. Deep learning of pharmacogenomics resources: moving towards precision oncology. Brief Bioinform. 2020;21:2066\u201383. https:\/\/doi.org\/10.1093\/bib\/bbz144.","journal-title":"Brief Bioinform"},{"key":"2184_CR96","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1039\/C7SC02664A","volume":"9","author":"Z Wu","year":"2018","unstructured":"Wu Z, Ramsundar B, Feinberg EN, et al. MoleculeNet: a benchmark for molecular machine learning. Chem Sci. 2018;9:513\u201330. https:\/\/doi.org\/10.1039\/C7SC02664A.","journal-title":"Chem Sci"},{"key":"2184_CR97","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41573-019-0024-5","volume":"18","author":"J Vamathevan","year":"2019","unstructured":"Vamathevan J, Clark D, Czodrowski P, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18:463\u201377. https:\/\/doi.org\/10.1038\/s41573-019-0024-5.","journal-title":"Nat Rev Drug Discov"},{"key":"2184_CR98","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1010933404324","volume":"45","author":"L Breiman","year":"2001","unstructured":"Breiman L. Random forests. Mach Learn. 2001;45:5\u201332. https:\/\/doi.org\/10.1023\/A:1010933404324.","journal-title":"Mach Learn"},{"key":"2184_CR99","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1136\/gutjnl-2021-324060","volume":"71","author":"R Sundar","year":"2022","unstructured":"Sundar R, Barr Kumarakulasinghe N, Huak Chan Y, et al. Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial. Gut. 2022;71:676\u201385. https:\/\/doi.org\/10.1136\/gutjnl-2021-324060.","journal-title":"Gut"},{"key":"2184_CR100","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btz682","author":"J Lee","year":"2019","unstructured":"Lee J, Yoon W, Kim S, et al. BioBERT: a pre-trained biomedical language representation model for biomedical text mining. Bioinformatics. 2019. https:\/\/doi.org\/10.1093\/bioinformatics\/btz682.","journal-title":"Bioinformatics"},{"key":"2184_CR101","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41598-020-80561-1","volume":"11","author":"A Paul","year":"2021","unstructured":"Paul A, Anand R, Karmakar SP, et al. Exploring gene knockout strategies to identify potential drug targets using genome-scale metabolic models. Sci Rep. 2021;11:213. https:\/\/doi.org\/10.1038\/s41598-020-80561-1.","journal-title":"Sci Rep"},{"key":"2184_CR102","doi-asserted-by":"crossref","first-page":"942.10","DOI":"10.1096\/fasebj.31.1_supplement.942.10","volume":"31","author":"VV Dukhande","year":"2017","unstructured":"Dukhande VV, Barot S, Husein S, Palaguachi C. Inhibition of glycogen metabolism as a potential strategy for anticancer therapy. FASEB J. 2017;31:942.10.","journal-title":"FASEB J"},{"key":"2184_CR103","doi-asserted-by":"publisher","first-page":"811.15","DOI":"10.1096\/fasebj.2018.32.1_supplement.811.15","volume":"32","author":"S Barot","year":"2018","unstructured":"Barot S, Abo-Ali EM, Palaguachi C, Dukhande VV. Insights into Glycogen Metabolic Inhibition-Induced Death of Hepatocellular Carcinoma. FASEB J. 2018;32:811.15.","journal-title":"FASEB J"},{"key":"2184_CR104","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1096\/fasebj.2019.33.1_supplement.652.1","volume":"33","author":"S Barot","year":"2019","unstructured":"Barot S, Abo-Ali EM, Zhou D, et al. Glycogen phosphorylase inhibition activates intrinsic apoptosis pathway and potentiates multi-kinase inhibitors in liver cancer cells. FASEB J. 2019;33:652\u201361.","journal-title":"FASEB J"},{"key":"2184_CR105","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.yexcr.2019.05.017","volume":"381","author":"S Barot","year":"2019","unstructured":"Barot S, Abo-Ali EM, Zhou DL, et al. Inhibition of glycogen catabolism induces intrinsic apoptosis and augments multikinase inhibitors in hepatocellular carcinoma cells. Exp Cell Res. 2019;381:288\u2013300.","journal-title":"Exp Cell Res"},{"key":"2184_CR106","unstructured":"Barot S (2021) Effect of inhibition of glycogen catabolism in hepatocellular carcinoma cells"},{"key":"2184_CR107","doi-asserted-by":"publisher","first-page":"115201","DOI":"10.1016\/j.bcp.2022.115201","volume":"203","author":"S Barot","year":"2022","unstructured":"Barot S, Stephenson OJ, Priya Vemana H, et al. Metabolic alterations and mitochondrial dysfunction underlie hepatocellular carcinoma cell death induced by a glycogen metabolic inhibitor. Biochem Pharmacol. 2022;203:115201. https:\/\/doi.org\/10.1016\/j.bcp.2022.115201.","journal-title":"Biochem Pharmacol"},{"key":"2184_CR108","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2174\/1874467211205010102","volume":"5","author":"J Zhang","year":"2012","unstructured":"Zhang J, Stevens MFG, Bradshaw TD. Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol. 2012;5:102\u201314. https:\/\/doi.org\/10.2174\/1874467211205010102.","journal-title":"Curr Mol Pharmacol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02184-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-023-02184-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02184-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T14:15:00Z","timestamp":1703340900000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-023-02184-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,7]]},"references-count":108,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["2184"],"URL":"https:\/\/doi.org\/10.1007\/s12032-023-02184-6","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,7]]},"assertion":[{"value":"29 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"324"}}